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BACKGROUND
Testing of vaccine candidates to prevent infection with severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since 
increased incidences of illness and death from coronavirus disease 2019 (Covid-19) 
have been associated with an older age.
METHODS
We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA 
vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike 
protein (S-2P) in healthy adults. The trial was expanded to include 40 older adults, 
who were stratified according to age (56 to 70 years or ≥71 years). All the partici-
pants were assigned sequentially to receive two doses of either 25 μg or 100 μg 
of vaccine administered 28 days apart.
RESULTS
Solicited adverse events were predominantly mild or moderate in severity and most 
frequently included fatigue, chills, headache, myalgia, and pain at the injection site. 
Such adverse events were dose-dependent and were more common after the second 
immunization. Binding-antibody responses increased rapidly after the first immuni-
zation. By day 57, among the participants who received the 25-μg dose, the anti–S-2P 
geometric mean titer (GMT) was 323,945 among those between the ages of 56 and 
70 years and 1,128,391 among those who were 71 years of age or older; among the 
participants who received the 100-μg dose, the GMT in the two age subgroups was 
1,183,066 and 3,638,522, respectively. After the second immunization, serum neu-
tralizing activity was detected in all the participants by multiple methods. Binding- 
and neutralizing-antibody responses appeared to be similar to those previously re-
ported among vaccine recipients between the ages of 18 and 55 years and were above 
the median of a panel of controls who had donated convalescent serum. The vaccine 
elicited a strong CD4 cytokine response involving type 1 helper T cells.
CONCLUSIONS
In this small study involving older adults, adverse events associated with the 
mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced 
higher binding- and neutralizing-antibody titers than the 25-μg dose, which sup-
ports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the Na-
tional Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study 
ClinicalTrials.gov number, NCT04283461.)
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The coronavirus disease 2019 (Covid-19) pandemic is an international public health emergency with major social and economic 
disruptions and devastating health consequences. 
The rapid development of vaccines is imperative. 
More than 30 vaccine candidates against severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), which causes Covid-19, have entered clini-
cal trials.1 Recently, in a phase 1, open-label trial, 
we reported that a messenger RNA vaccine, 
mRNA-1273, which encodes SARS-CoV-2 prefu-
sion-stabilized spike protein, had an acceptable 
safety and reactogenicity profile and was im-
munogenic in participants between the ages of 
18 and 55 years.2 Two injections of this vaccine, 
spaced 28 days apart, resulted in neutralizing-
antibody responses similar to those elicited by 
convalescent serum obtained from patients who 
had recovered from Covid-19 infection. Mice and 
rhesus macaques that were given mRNA-1273 
and were subsequently challenged with high-dose 
intranasal SARS-CoV-2 rapidly cleared the virus 
from the upper and lower airways.3,4
The immune response to many other vaccines 
has been shown to decrease with increasing age.5 
Thus, the testing of SARS-CoV-2 vaccine candi-
dates in older populations is of paramount im-
portance, since these persons account for the 
majority of serious Covid-19 cases and associated 
deaths.6,7 Here, we report preliminary safety and 
immunogenicity data for the mRNA-1273 vac-
cine in an expansion of the phase 1 trial among 
healthy participants who were 56 years of age or 
older.
Me thods
Trial Design and Participants
We initially conducted a phase 1, dose-escala-
tion, open-label clinical trial of mRNA-1273 in-
volving participants between the ages of 18 and 
55 years2 in which we evaluated doses of 25 μg, 
100 μg, and 250 μg. We subsequently expanded 
the trial to include 40 participants who were 56 
years of age or older and who were stratified 
into two subgroups: those between the ages of 
56 and 70 years and those who were 71 years of 
age or older. Because of clinically significant 
systemic reactogenicity observed in participants 
between the ages of 18 and 55 years at the 250-μg 
dose, we administered doses of 25 μg or 100 μg 
to the older participants.
The trial was conducted at Kaiser Permanente 
Washington Health Research Institute in Seattle, 
the Emory University School of Medicine in At-
lanta, and the National Institute of Allergy and 
Infectious Diseases (NIAID) Vaccine Research 
Center in Bethesda, Maryland. Enrolled adults 
were healthy and provided written informed con-
sent before undergoing any study procedures. We 
did not screen for evidence of past or current 
SARS-CoV-2 infection by testing blood or nasal 
specimens before enrollment. Full eligibility crite-
ria, along with details of the trial design, conduct, 
oversight, and statistical analyses, are described 
in the protocol, which is available with the full 
text of this article at NEJM.org.
mRNA-1273 Vaccine
The mRNA-1273 vaccine was codeveloped by re-
searchers at the NIAID Vaccine Research Center 
and Moderna in Cambridge, Massachusetts. This 
vaccine encodes a stabilized version of the SARS-
CoV-2 full-length spike glycoprotein trimer, S-2P, 
which has been modified to include two proline 
substitutions at the top of the central helix in 
the S2 subunit. The mRNA is encapsulated in 
lipid nanoparticles at a concentration of 0.5 mg 
per milliliter and diluted with normal saline to 
achieve the final target vaccine concentrations.
Study Oversight
The NIAID served as the trial sponsor and made 
all decisions regarding the study design and im-
plementation. The vaccine Investigational New 
Drug application and the protocol amendment 
expanding the age subgroups were reviewed by 
the Food and Drug Administration and the insti-
tutional review board at Advarra, a regulatory 
compliance consulting company, which served 
as the single institutional review board for all 
the study sites. An independent data and safety 
monitoring committee reviewed interim safety 
reports.
Moderna provided mRNA-1273 for use in this 
trial but did not provide any financial support. 
Employees of Moderna collaborated on the devel-
opment of the protocol, contributed to the Inves-
tigational New Drug application, and participated 
in weekly team meetings regarding the study.
Emmes, the statistical and data coordinating 
center for the study, developed the statistical 
analysis plan and performed all data analyses. 
Data reports, which were generated from the 
A Quick Take 
is available at 
NEJM.org
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raw data by the statistical and data coordinating 
center, were provided and available to all the 
authors. The manuscript was written entirely by 
the authors, with the first two authors serving 
as overall lead authors. All the authors vouch for 
the completeness and accuracy of the data and 
for the adherence of the study to the protocol. 
No one who is not an author contributed to the 
writing of the manuscript.
Trial Procedures
The mRNA-1273 vaccine was administered as a 
0.5-ml intramuscular injection into the deltoid 
on days 1 and 29 of the study; the same dose of 
the vaccine was administered on both days. 
Follow-up visits were scheduled 7 and 14 days 
after the administration of each dose of vaccine 
and on day 57. A standard toxicity scale was used 
to grade adverse events (Table S1 in the Supple-
mentary Appendix, available at NEJM.org). Solic-
ited local and systemic adverse events were col-
lected for 7 days after each vaccination, as 
facilitated by the use of a memory aid. Data re-
garding unsolicited adverse events and the use 
of new medications were collected through day 
57. Collection of specimens, as well as monitor-
ing for medically attended adverse events, devel-
opment of new chronic medical conditions, and
serious adverse events, was scheduled to con-
tinue through 1 year after the last dose. These
initial findings will be updated with final safety
and immunogenicity data when the results are
available.
After the initial safety data from the first 
phase of the study were available from partici-
pants between the ages of 18 and 55 years,2 the 
administration of mRNA-1273 was initiated se-
quentially in the subgroup of participants be-
tween the ages of 56 and 70 years at the 25-μg 
dose, which was followed by the initiation of the 
100-μg dose. Since no halting rules were met 
after the participants in this subgroup had com-
pleted day 8, vaccine administration was initiat-
ed sequentially in the subgroup of participants 
who were 71 years of age or older at the 25-μg 
dose, which was followed by the initiation of the 
100-μg dose.
Assessment of Antibody Responses
We performed enzyme-linked immunosorbent 
assays (ELISA) to quantify the binding IgG re-
sponses to S-2P containing an Asp (D) residue at 
position 614 (initial Wuhan-1 strain sequence8) 
and to the receptor-binding domain on days 1, 
15, 29, 36, 43, and 57. (The receptor-binding 
domain is the portion of the SARS-CoV-2 virus 
that is located on its spike domain and that links 
with body receptors to infect cells.) A SARS-
CoV-2 native spike-pseudotyped lentivirus re-
porter single-round-of-infection neutralization 
assay (pseudovirus neutralization assay) was 
used to assess vaccine-induced neutralizing ac-
tivity against the 614D variant at the same time 
points. Vaccine-induced neutralization on day 43 
was assessed with a second pseudovirus neutral-
ization assay with the use of the 614-Gly (614G) 
polymorphic variant, since the 614G strain had 
become predominant in both the United States 
and worldwide.9 (Details are provided in the 
Methods section in the Supplementary Appendix.)
Three live-virus neutralization methods were 
used: first, the SARS-CoV-2 nanoluciferase high-
throughput neutralization assay (nLuc HTNA), 
which uses a virus expressing the reporter gene 
nanoluciferase (nLuc)10; second, the focus reduc-
tion neutralization test mNeonGreen (FRNT-
mNG), which uses recombinant SARS-CoV-2 
expressing the fluorescent reporter gene mNeon-
Green11; and third, a SARS-CoV-2 plaque-reduc-
tion neutralization testing (PRNT) assay, which 
uses wild-type virus. We used the nLuc HTNA to 
analyze specimens that were obtained on days 1, 
29, and 43 from the participants who were 56 
years of age or older and who received the 100-μg 
dose. We used the FRNT-mNG assay to analyze 
specimens obtained on days 1, 29, and 43 from 
all the participants in the two age and dose sub-
groups. For this preliminary report, because of 
the time-intensive nature of the PRNT assay and 
to maximize usable information obtained from 
its use, we performed PRNT assays for the pres-
ence of SARS-CoV-2 on samples obtained on 
days 1 and 43 from participants who received 
the 100-μg dose only. We used as comparators 
previously reported results for participants be-
tween the ages of 18 and 55 years who had been 
enrolled in the 100-μg subgroup, as well as re-
sults from controls who had donated convales-
cent serum.2 The severity of Covid-19 illness was 
known for 38 of these controls and was classi-
fied as mild in 63% of the participants, moder-
ate in 22%, and severe (defined as hospitaliza-
tion requiring intensive care, ventilation, or both) 
in 15%.
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Assessment of T-Cell Responses
Intracellular cytokine-staining assays were per-
formed to quantify antigen-specific T-cell respons-
es against the spike protein on days 1, 29, and 43. 
(Details are provided in the Supplementary Ap-
pendix.)
Statistical Analysis
Safety analyses included all the participants who 
had received at least one dose of mRNA-1273. 
Immunogenicity results excluded specimens that 
had been obtained after day 29 in a participant 
who had received only a single dose of vaccine. 
No other data points were missing. Seroconversion 
was defined as an increase from baseline in the 
antibody titer by a factor of 4 or more. Geometric 
means were calculated by log transforming the 
data points and calculating the mean and 95% 
confidence interval on the log-transformed data. 
The log-transformed mean and 95% confidence 
interval were then back-transformed to the orig-
inal scale. We used the Student’s t-test to calcu-
late confidence intervals. Interim analyses in the 
study subgroups were prespecified to inform criti-
cal decisions about vaccine development.
R esult s
Trial Population
Forty participants, 10 in each of the two age and 
dose subgroups, were enrolled between April 16 
and May 12, 2020 (Fig. S1). The demographic 
characteristics of the participants are shown in 
Table 1. One participant who was between the 
ages of 56 and 70 years in the 100-μg subgroup 
did not receive a second vaccination or have blood 
collected after day 29. (Details regarding this 
participant are provided in the following section.)
Vaccine Safety
No serious adverse events were reported, and no 
prespecified trial-halting rules were met. Two 
days after vaccination, paronychia (infection of 
the tissue adjacent to a nail) developed in one 
participant who was between the ages of 56 and 
70 years in the 100-μg subgroup. This participant 
was treated with trimethoprim–sulfamethoxa-
zole, and 7 days later, a diffuse maculopapular 
rash developed. The rash was considered by in-
vestigators to be unrelated to vaccination and 
was treated with systemic administration of 
glucocorticoids. This participant did not receive 
a second vaccination.
The most common solicited adverse events 
were headache, fatigue, myalgia, chills, and in-
jection-site pain (Fig. 1). Local and systemic re-
actogenicity events were more common and 
were predominantly moderate in severity after 
the administration of the second dose of vac-
cine. All 10 solicited local adverse events that 
were classified as moderate, and all but 2 mod-
erate systemic events, occurred after the admin-
Table 1. Characteristics of the Participants at Baseline.*












Sex — no. (%)
Male 3 (30) 5 (50) 8 (80) 3 (30) 19 (48)
Female 7 (70) 5 (50) 2 (20) 7 (70) 21 (52)
Age — yr 65.8±4.5 63.8±4.3 72.8±1.2 72.6±1.1 68.7
Race or ethnic group — no. (%)†
Asian 0 0 1 (10) 0 1 (2)
White 10 (100) 10 (100) 9 (90) 10 (100) 39 (98)
Hispanic or Latino 0 0 1 (10) 0 1 (2)
Body-mass index‡ 25.4±2.5 23.7±2.3 24.8±3.5 26.0±3.5 25.0±3.0
*  Plus–minus values are means ±SD.
†  Race or ethnic group was reported by the participants, who could select more than one category.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
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istration of the second dose (Fig. 1 and Table S2). 
These symptoms typically occurred on the day of 
vaccination or 1 day afterward and resolved 
quickly. Three participants had erythema that 
lasted for 5 to 7 days; all the cases were mild 
and began on day 1 or 2. One participant had 
mild myalgia symptoms that began on day 3 and 
lasted for 5 days. Two solicited systemic adverse 
events that were classified as severe (grade 3) 
occurred after the second dose: fever in a par-
ticipant between the ages of 56 and 70 years in 
the 25-μg dose subgroup and fatigue in a par-
ticipant who was 71 years of age or older in the 
100-μg dose subgroup. A total of 71 unsolicited 
adverse events were reported, of which 17 were 
considered by the investigators to be related to 
the vaccine and are detailed in Table S3. All re-
lated unsolicited adverse events were mild except 
for a single event of moderate severity, which 
was decreased appetite in a participant who was 
between the ages of 56 and 70 years in the 25-μg 
dose subgroup. The single severe (grade 3) unso-
licited adverse event was hypoglycemia (glucose 
level, 50 mg per deciliter [2.8 mmol per liter]; 
reference range, 65 to 99 mg per deciliter [3.6 to 
5.5 mmol per liter]), which occurred in a par-
ticipant who was between the ages of 56 and 70 
years in the 100-μg dose subgroup after fasting 
and vigorous exercise and was considered by the 
investigators to be unrelated to the vaccine. 
Clinical laboratory values of grade 2 or higher 
are detailed in the Supplementary Appendix.
Binding-Antibody Responses
Data were available for all the participants at all 
time points except for the period after day 29 in 
the participant who did not receive a second vac-
cine dose. At baseline, some participants had 
detectable serum binding-antibody responses in 
the receptor-binding domain and in S-2P IgG on 
ELISA. Binding IgG antibody geometric mean 
titers (GMTs) to S-2P and receptor-binding do-
main increased rapidly after the first vaccina-
tion. Dose-dependent responses to the first and 
second doses of vaccine were evident, and after 
the second vaccination, responses reached the 
upper quarter of the distribution of responses 
among controls who had donated convalescent 
serum (Fig. 2A, Figs. S2 and S3, and Tables S4 
and S5). On the S-2P ELISA, the GMT at day 57 
in the 25-μg subgroup was 323,945 (95% confi-
dence interval [CI], 182,202 to 575,958) among 
participants who were between the ages of 56 
and 70 years and 1,128,391 (95% CI, 636,087 to 
2,001,717) among those who were 71 years of 
age or older. These responses were greater than 
those observed among participants who had 
donated convalescent serum (GMT, 138,901; 
95% CI, 82,876 to 232,799). The GMTs of the 
participants in the 100-μg subgroup far exceed-
ed the responses among participants who had 
donated convalescent serum: 1,183,066 GMT 
(95% CI, 379,698 to 3,686,201) among partici-
pants who were between the ages of 56 and 70 
years and 3,638,522 GMT (95% CI, 1,316,233 to 
10,058,130) among those who were 71 years of 
age or older.
Neutralization Responses
Titers to 614D on the pseudovirus neutralization 
assay were undetectable before vaccination and 
showed dose-dependent responses that were 
observed as early as 7 days after the second dose 
(day 36) in an age-independent manner. At day 
43, on the pseudovirus neutralization assay, the 
50% inhibitory dilution (ID50) titers to 614D that 
were induced by the 100-μg dose were similar 
among the participants who were between the 
ages of 56 and 70 years (GMT, 402; 95% CI, 289 
to 560) and those who were 71 years of age or 
older (GMT, 317; 95% CI, 198 to 508) (Fig. 2B 
and Tables S4 and S5); the responses were also 
similar to those previously reported for partici-
pants between the ages of 18 to 55 years. Re-
sponses to the 100-μg dose were higher than 
responses to the 25-μg dose and than responses 
among controls who had donated convalescent 
serum. Robust neutralizing activity to the 614G 
variant was observed for the 100-μg dose re-
gardless of the participant’s age (Fig. S5 and 
Tables S4 and S5). Neutralizing activity re-
mained high through 4 weeks after the admin-
istration of the second dose in all the subgroups.
Neutralizing responses were undetectable by 
nLuc HTNA, FRNT-mNG, or PRNT at baseline 
(Fig. 2C and 2D, Figs. S6 and S7, and Tables S4 
and S5). Potent neutralization responses were 
observed in all the participants 14 days after the 
second dose of vaccine (on day 43). Responses to 
the 100-μg dose on day 43 on nLuc HTNA and 
FRNT-mNG were similarly high across age strata; 
the PRNT80 (80% inhibitory dilution) GMT was 
878 (95% CI, 516 to 1494) among participants 
who were between 56 and 70 years of age and 
317 (95% CI, 181 to 557) among those who were 
71 years of age or older.
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Similar to the results among the participants 
who were between the ages of 18 to 55 years, the 
receptor-binding domain and S-2P ELISA titers 
correlated with the results on the pseudovirus 
neutralization assay in the older subgroups. In 
addition, all the neutralization assays — pseu-
dovirus neutralization assay, nLuc HTNA, FRNT-
mNG, and PRNT — correlated well with each 
other and with the receptor-binding domain 
ELISA; the results on the PRNT assay did not 
correlate well with the results on the S-2P ELISA 
(Figs. S8 through S12).
T-Cell Reponses
In response to S-specific peptide pools, the vac-
cine elicited a strong CD4 cytokine response in-
volving type 1 helper T (Th1) cells among par-
ticipants in the two age subgroups who received 
the 100-μg dose and among participants be-
tween the ages of 56 and 70 years who received 
the 25-μg dose; the tumor necrosis factor α re-
sponses were greater than the interleukin-2 re-
sponses, which in turn were greater than the 
interferon-γ responses (Fig. 3 and Fig. S13). In 
the subgroup of participants who received the 
25-μg dose, the cytokine response was lower 
among those who were 71 years of age or older 
than among those in the other subgroup. The 
response involving type 2 helper T cells (inter-
leukin-4 and interleukin-13) was minimal regard-
less of age or dose. CD8 T-cell responses to S-2P 
were observed only at low levels after the second 
vaccination among the participants in the two 
age subgroups who received the 100-μg dose 
(Fig. S14).
Discussion
In our study population of older participants 
(≥56 years of age), the two-dose vaccine series 
had an acceptable safety and reactogenicity pro-
file at doses of both 25 μg and 100 μg with 
mostly mild-to-moderate local and systemic ad-
verse events of short duration, which occurred 
predominantly after the second dose. We did not 
observe systematic differences in the reactogen-
icity profile between this older cohort and par-
ticipants between the ages of 18 and 55 years 
who had received the mRNA-1273 vaccine.2 Our 
findings were also similar to the results of other 
trials of mRNA vaccines involving younger 
adults.12,13 Owing to the small number of par-
ticipants in each group, formal statistical com-
parisons of between-subgroup age effects are 
not meaningful. Our planned 13-month follow-
up allows for a longer duration of assessment of 
vaccine-related adverse events, although the lim-
ited sample size may not capture rare serious 
adverse events.2
As of this writing, no correlate of protection 
for SARS-CoV-2 has been established. However, 
neutralizing-antibody levels have been shown to 
correlate with protection against many viruses 
in humans14 and have correlated with protection 
against SARS-CoV-2 in animal challenges.3,15 The 
mRNA-1273 vaccine induced high levels of both 
binding and neutralizing antibodies in older 
adults, and the time- and dose-dependent trends 
were similar to responses in younger adults2; the 
responses after the second vaccination were 
similar to those observed in patients who had 
recovered from Covid-19 and had donated conva-
lescent serum, including some who were se-
verely ill. We must acknowledge that these as-
sessments are qualitative; the small number of 
participants in each age and dose subgroup 
limits the power of efforts at quantitative assess-
ment. Antibody and T-cell responses that were 
observed in this older population who received 
the 100-μg dose exceeded the response to the 
25-μg dose and were similar to the response 
among participants between the ages of 18 and 
55 years who received the 100-μg dose.2 These 
data also suggest that a second dose of vaccine 
is needed to achieve neutralizing antibodies in 
participants after the age of 56 years, and titers 
rapidly increased by 7 days after the booster vac-
cination. We found strong correlations between 
the receptor-binding domain ELISA and all neu-
tralization assays. These findings suggest that 
the receptor-binding domain ELISA and higher-
Figure 1 (facing page). Solicited Systemic and Local Ad-
verse Events within 7 Days after Receipt of mRNA-1273.
Shown are data for older participants in the two age 
subgroups (56 to 70 years and ≥71 years) and the two 
dose subgroups (25 μg and 100 μg). The severity of so-
licited adverse events was graded as mild, moderate, or 
severe on the basis of definitions that are detailed in 
Table S1 in the Supplementary Appendix. Dashes indi-
cate that the adverse event was not reported in any par-
ticipant.
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throughput neutralization methods (e.g., pseudo-
virus neutralization assay, FRNT-mNG, and nLUC 
HTNA) could be used in a complementary man-
ner to assess immunogenicity of SARS-CoV-2 
vaccines and potentially to confirm an immuno-
logic correlate of protection that would support 
public-health decision making regarding vacci-
nation strategies.
Our assessments of antibody responses have 
focused on the 614D strain (the initial Wuhan-1 
strain sequence), although the 614G polymor-
phism in SARS-CoV-2 spike has rapidly spread to 
become the globally predominant isoform,9 which 
suggests a selective advantage. However, we ob-
served an increase in neutralizing activity on the 
pseudovirus neutralization assay when 614G was 
substituted for 614D. These data are consistent 
with results in mice that were vaccinated with 
mRNA-127316 and with observations from con-
valescent donor serum.9 These data are reassur-
ing that immune responses to mRNA-1273 may 
not be compromised by the presence of the 614G 
strain.
Typically, immunosenescence renders older 
adults more susceptible to infection and hinders 
the development of protective immunity after 
immunization17 with selected vaccines (e.g., re-
duced immunogenicity of the live-attenuated 
shingles vaccine).18 Potently immunogenic vac-
cine designs are particularly relevant for older 
adults, since severe or fatal cases of Covid-19 
occur more often in this population.6 Although 
the sample sizes in our study were limited, older 
participants (including those who were 71 years 
of age or older) had immunologic responses to 
the mRNA-1273 vaccine 1 month after the sec-
ond dose and across multiple assays that were 
similar to the responses among younger partici-
pants. We did not observe systematic differences 
in binding-antibody responses between the two 
older-age subgroups and the younger popula-
tion, although slight decreases in PRNT80 were 
observed in those who were 71 years of age or 
older, as has been seen with other vaccines.13 It 
is possible that the mRNA-1273 vaccine may 
activate memory B cells that recognize shared 
antigenic determinants between spike proteins 
of SARS-CoV-2 and endemic human coronavi-
ruses, which could also account for low binding-
antibody levels detected in some prevaccination 
specimens. These findings are consistent with 
those of Ledgerwood et al., who observed age-
independent responses to a West Nile virus DNA 
vaccine.19 The mRNA-1273 platform offers sev-
eral potential advantages for stimulation of pro-
tective responses in older populations, including 
the generation of a more immunogenic spike 
protein than that in wild-type virus owing to 
prefusion-stabilizing mutations,16,20 the ability to 
control innate immune stimulation through mRNA 
modification,10 and the efficient uptake into 
human cells due to its lipid nanoparticle formu-
lation.21
Important limitations of this study include 
the small numbers of participants and the lim-
ited ethnic diversity. In addition, at the time of 
this interim report, the long-term durability of 
immunogenicity could not be assessed, although 
the magnitude of antibody, cellular, and memo-
ry responses will be followed for 12 months af-
ter the second vaccination. Waning neutralizing-
antibody titers have been observed in recipients 
of DNA vaccines against MERS (Middle East re-
spiratory syndrome) and SARS22,23 and in patients 
with SARS-CoV-2 infection.24,25 Data on the dura-
bility of responses observed after mRNA vac-
cines are limited. However, the administration 
of an mRNA H7N9 influenza vaccine resulted in 
detectable antibody titers in participants 6 months 
after vaccination.26 It is possible that early induc-
tion of high-magnitude antibody responses could 
extend the duration of detectable titers, as has 
been seen with other vaccines.27 Finally, the pres-
Figure 2 (facing page). SARS-CoV-2 Antibody-Binding 
and Neutralization Responses.
Shown are reciprocal end-point binding IgG titers on 
receptor-binding domain (RBD) enzyme-linked immu-
nosorbent assay (ELISA) (Panel A), along with titers to 
614D on the pseudovirus neutralization assay at a 50% 
inhibitory dilution (ID50) (Panel B), on the focus reduc-
tion neutralization test mNeonGreen assay (FRNT-
mNG ID50) (Panel C), and on plaque-reduction neutral-
ization testing (PRNT80) (Panel D).2 PRNT80 results 
were available only for the participants who had re-
ceived the 100-μg dose of the mRNA-1273 vaccine on 
days 1 and 43. Boxes denote interquartile ranges, and 
horizontal bars denote median end-point titers. Whis-
ker end points denote the maximum and minimum val-
ues below or above the median at 1.5 times the inter-
quartile range. The shaded portion on the right side of 
each panel indicates one or two categories of reference 
values: antibody titers from 41 controls who had donat-
ed convalescent serum (Panels A and B) and antibody 
titers from participants between the ages of 18 and 55 
years who had received the 100-μg dose of mRNA-1273 
(Panels A through D).2
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ence of chronic diseases (e.g., diabetes) and 
frailty may be better predictors of poor immuno-
logic responses than age alone.28
Overall, these preliminary findings show that 
in a small group of participants, adverse events 
associated with the mRNA-1273 vaccine were 
mainly mild or moderate in older adults, a group 
that is particularly at risk for illness and death 
from Covid-19. The 100-μg dose induced higher 
binding- and neutralizing-antibody titers than the 
25-μg dose, findings that support the continued 
evaluation of the 100-μg dose level and two-dose 
regimen in a large phase 3 trial with a more di-
verse population to ascertain the safety and effi-
cacy of the mRNA-1273 vaccine and to assess its 
level of protection against Covid-19.
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